Reviva Pharmaceuticals Holdings, Inc. (RVPH): Total Liabilities
$7.28M
As of 2025-12-31
$5.93M
As of 2026-06-30
-11.6%
3-year compound annual growth
+17.2%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $7.28M | -50.5% | 2026-03-30, Balance as of period end |
| 2024-12-31 | $14.69M | -18.3% | 2026-03-30, Balance as of period end |
| 2023-12-31 | $17.98M | n/a | 2025-04-03, Balance as of period end |
| 2023-09-30 | $18.20M | n/a | 2024-04-15, Balance as of period end |
| 2023-06-30 | $13.66M | n/a | 2024-04-15, Balance as of period end |
| 2023-03-31 | $11.29M | n/a | 2024-04-15, Balance as of period end |
| 2022-12-31 | $10.53M | n/a | 2024-04-15, Balance as of period end |
| 2022-09-30 | $6.49M | n/a | 2024-04-15, Balance as of period end |
| 2021-12-31 | $2.72M | -17.6% | 2023-03-30, Balance as of period end |
| 2020-12-31 | $3.30M | n/a | 2022-03-15, Balance as of period end |
| 2020-02-29 | $3.26M | n/a | 2020-05-04, Balance as of period end |
| 2019-12-31 | $6.81M | n/a | 2021-05-07, Balance as of period end |
| 2019-02-28 | $2.24M | n/a | 2020-05-04, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Reviva Pharmaceuticals Holdings, Inc. (RVPH) | 2025-12-31 | $7.28M | -50.5% |
| Anixa Biosciences Inc (ANIX) | 2025-10-31 | $2.13M | -21.2% |
| Aditxt, Inc. (ADTX) | 2025-12-31 | $12.56M | -47.3% |
| Cingulate Inc. (CING) | 2025-12-31 | $12.56M | +69.6% |
| Cellectar Biosciences, Inc. (CLRB) | 2025-12-31 | $5.06M | -48.4% |
| Tempest Therapeutics, Inc. (TPST) | 2025-12-31 | $10.26M | -54.1% |
| Lipocine Inc. (LPCN) | 2025-12-31 | $2.53M | +67.1% |
| Impact Biomedical Inc. (IBO) | 2025-12-31 | $1.85M | -85.8% |
| Mustang Bio, Inc. (MBIO) | 2025-12-31 | $8.06M | -38.8% |
Compare RVPH, ANIX, ADTX, CING side by side · Screen every company in Pharmaceutical Preparations ↗